Durable Near-Complete Response to Olaparib Plus Temozolomide and Radiation in a Patient With ATM-Mutated Glioblastoma and MSH6-Deficient Lynch Syndrome

Lignende værker

• Treatment of Pediatric Glioblastoma with Combination Olaparib and Temozolomide Demonstrates 2‐Year Durable Response
  af: Valiakhmetova, Andge, et al.
  Udgivet: (2019)
• The Combination PARP Inhibitor Olaparib With Temozolomide in an Experimental Glioblastoma Model
  af: HWANG, KIHWAN, et al.
  Udgivet: (2021)
• Accelerated hyperfractionation plus temozolomide in glioblastoma
  af: Kaul, David, et al.
  Udgivet: (2016)
• MSH6 mutations arise in glioblastomas during temozolomide therapy and mediate temozolomide resistance
  af: Yip, Stephen, et al.
  Udgivet: (2009)
• PARADIGM-2: Two parallel phase I studies of olaparib and radiotherapy or olaparib and radiotherapy plus temozolomide in patients with newly diagnosed glioblastoma, with treatment stratified by MGMT status
  af: Fulton, Ben, et al.
  Udgivet: (2017)